CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION

The evaluation of the clinical efficacy and renoprotective effects of olmesartan and lercanidipine as monotherapy and when combined application in patients with arterial hypertension (AH) 1-2 degrees and microalbuminuria (MAU).It is established that the degree of blood pressure (BP) reduction and co...

Full description

Saved in:
Bibliographic Details
Published inKliničeskaâ praktika Vol. 7; no. 1; pp. 11 - 21
Main Authors Evdokimova, A G, Ryzhova, Yu V, Gukolenko, L V
Format Journal Article
LanguageEnglish
Published Eco-vector 15.03.2016
Subjects
hypertension
lercanidipine
microalbuminuria
nephroprotection
olmesartan
Online AccessGet full text

Cover

More Information
Summary:The evaluation of the clinical efficacy and renoprotective effects of olmesartan and lercanidipine as monotherapy and when combined application in patients with arterial hypertension (AH) 1-2 degrees and microalbuminuria (MAU).It is established that the degree of blood pressure (BP) reduction and corrective influence on diurnal BP profile were similar in groups of monotherapy with olmesartan and lercanidipine. In the group of combined application of the studied drugs target BP levels were achieved in 88% of cases in the monotherapy group and 78% (1G) and 76% (2 G).Revealed renoprotective effects of olmesartan and lercanidipine as when used in monotherapy and in combination in patients with arterial hypertension of 1-2 degrees, and MAU, revealed reliable decrease in MAU. The greatest reduction in MAU was achieved in the combination therapy group.
ISSN:2220-3095
2618-8627
DOI:10.17816/clinpract7111-21